A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

Trial Profile

A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Bladder cancer; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 23 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 23 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 18 Feb 2017 Results (n=6) presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top